Merck’s Zostavax Sales Plummet, Injury Lawsuits Mount
Zostavax is bringing pain for both users and its maker, according to recent reports. The shingle vaccine’s sales are dropping as manufacturer Merck begins to face a rash of Zostavax injury lawsuits. In the first quarter of 2018, Merck reported Zostavax made $65 million. The figure is 58 percent…
